A joint study conducted by scientists from China, Taiwan and Australia showed that the use
The clinical trial was conducted on patientswho were diagnosed with type II diabetes between 2000 and 2012. The biologists used a national database in Taiwan and examined the performance of 40,694 patients, of whom 20,347 received metformin and 20,347 did not. The average age of participants was 63 years.
Scientists compared the results of those who tookmetformin, and those who did not take it. It turned out that daily use of the drug reduces the risk of bone disease. Thus, the need for total replacement of the knee and hip joints was reduced by 30%.
According to an article published in the magazineCanadian Medical Association, the results indicate the potential therapeutic value of metformin for patients with osteoarthritis. However, the study authors noted that randomized controlled clinical trials are needed to confirm the effectiveness of the drug in patients with osteoarthritis.
Osteoarthritis is a chronic disease that causes severe pain and stiffness in the joints. In severe cases, the patient requires a total knee or hip replacement.
Diabetes mellitus is a known risk factorosteoarthritis regardless of body mass index. Previous studies have shown that insulin resistance also contributes to the development of this bone disease. Due to its hypoglycemic effect, metformin is often prescribed for the treatment of diabetes mellitus.
Read more:
17-year-old engineer came up with a magnetless motor: it can be used in electric vehicles
Two planets have been found not far from Earth. Perhaps they are inhabited
A unique meteor rewrote the history of the solar system: where did it come from